Puma BiotechnologyCOVID-19 UPDATE

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to

Home About Us Pipeline News Investors Contacts Careers

Final efficacy results of neratinib in HER2-positive hormone receptor-positive early stage breast cancer from the Phase III ExteNET trial have been published in Clinical Breast Cancer. The full manuscript is available below:A Phase II trial evaluating diarrhea management strategies for NERLYNX® tablets, including dose escalation, has been published in the Annals of Oncology. The full manuscript is available below:
Corporate Fact Sheet

RECENT NEWSEVENTSCLINICAL TRIALS


Oct. 21, 2021 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read

Sept. 21, 2021 - Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference
Read

Sept. 7, 2021 - Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Read

Aug. 5, 2021 - Puma Biotechnology Reports Second Quarter 2021 Financial Results
Read

July 26, 2021 - Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital
Read

July 22, 2021 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read

July 15, 2021 - NCCN Announces Selected Projects to Study Neratinib in Collaboration with Puma Biotechnology, Inc.
Read

July 1, 2021 - FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer
Read

June 4, 2021 - Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting
Read

June 4, 2021 - Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting
Read

June 4, 2021 - Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting
Read

May 19, 2021 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting
Read

May 6, 2021 - Puma Biotechnology Reports First Quarter 2021 Financial Results
Read

April 22, 2021 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read

Upcoming Events

Oct. 21, 2021 - Puma Biotechnology 3Q-2021 Financial Results Conference Call
More


Past Events

Sept. 28, 2021 - Cantor Virtual Global Healthcare Conference
More

Sept. 13-15, 2021 - H.C. Wainwright 23rd Annual Global Investment Conference
More

Aug. 5, 2021 - Puma Biotechnology 2Q-2021 Financial Results Conference Call
More

June 4-8, 2021 - ASCO 2021 Annual Meeting
More

May 6, 2021 - Puma Biotechnology 1Q-2021 Financial Results Conference Call
More

Mar. 11, 2021 - Barclays Global Healthcare Conference
More

Mar. 9, 2021 - H.C. Wainwright Global Life Sciences Conference
More

Mar. 2, 2021 - Cowen and Company 41st Annual Health Care Conference
More

Feb. 25, 2021 - Puma Biotechnology 4Q-2020 Financial Results Conference Call
More

Jan. 26-29, 2021 - IASLC 2021 World Conference on Lung Cancers
More

Jan. 21, 2021 - B. Riley Oncology Investor Conference
More

Jan. 15-17, 2021 - ASCO 2021 Gastrointestinal Cancers Symposium
More

Jan. 14, 2021 - 39th Annual J.P. Morgan Healthcare Conference
More

Jan. 11, 2021 - H.C. Wainwright VIRTUAL BioConnect Conference
More

 Puma-Sponsored Trials
Investigator-Sponsored Trials



Annual Report

2020 Annual Report


 Annual Report Archives

Contact

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax

Medical Inquiries:
1-844-MED-PUMA (1-844-633-7862), or
medinfo@pumabiotechnology.com

Business Development:
info@pumabiotechnology.com

Investor Relations:
ir@pumabiotechnology.com

Follow Us:




© 2021 Puma Biotechnology, Inc. | Privacy Policy | Legal Notice | Site Map